For instance, a decrease in radiotracer accumulation in normal organs in patients with high tumor burden has been reported for theranostic targets other than CXCR4 [11], e.g., for somatostatin receptor (SSTR) and prostate specific membrane antigen (PSMA)-targeting radiotracers [11, 12]. This evidence concerns the gene FOLH1 and neoplasm.